Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-news-1/unc-scientists-garner-new-nih-awards-for-high-risk--transformative-research-10076-4/;/a><br) was not found.

Search biology news 1 unc scientists garner new nih awards for high risk transformative research 10076 4 ; a><br at Google

Search biology news 1 unc scientists garner new nih awards for high risk transformative research 10076 4 ; a><br at Yahoo

Search biology news 1 unc scientists garner new nih awards for high risk transformative research 10076 4 ; a><br at Msn

Google
 
(Date:12/3/2009)... staph infections are caused by many bacterial cells that signal ... quorum sensing because many bacteria must be present to start ... determined that the very first stage of staph infection, when ... in a single cell and that this individual process can ...
(Date:12/3/2009)... past three years in the troposphere (lower atmosphere) over ... which are the first of their kind in the ... 2002 and 2005. , Over recent years, physicists and ... dioxide (CO2) levels, and how these have evolved in ...
(Date:12/2/2009)... more difficult time quitting smoking than those who are ... affect on Latinas odds of quitting smoking. Details of ... & Prevention , a journal of the American Association ... focus on tobacco. , "Acculturation affects smoking cessation differently ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Acculturation affects smoking cessation success among Latinos 2Online Genetic Testing Appears to Have Benefits 50454 1Online Genetic Testing Appears to Have Benefits 50454 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 1More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 3Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 12856 1Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 12856 2
(Date:12/5/2009)... ORLEANS, Dec. 5 There have been significant scientific ... experts continue to gain a better understanding of how ... options and provide patients with the best care. Research ... American Society of Hematology explores optimal induction therapies for ...
(Date:12/5/2009)... Dec. 5 Leukemia and myeloproliferative disorders are ... today at the 51st Annual Meeting of the ... options and improved diagnostic methods for patients suffering ... acute lymphoblastic leukemia, and myelofibrosis that are based ...
(Date:12/5/2009)... International Solutions, an innovative new international private medical insurance plan which ... to offering customers the flexibility to add or remove a wide ... enables customers to tailor their benefits to complement those already offered ... ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ) ("Care" ... declared a dividend of $0.17 per share of common stock. ... of record on December 14, 2009. ,, ... a real estate investment and finance company investing in healthcare-related real ...
(Date:12/4/2009)... WASHINGTON, Dec. 4 The American Association of Homes and ... that the Community Living and Supportive Services (CLASS) provisions ... provisions are essential for providing support to elders, people with ... to pass a health care reform bill that will make ...
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
Polyclonal Antibody to Golgin-67...
Polyclonal Antibody to AHI1 / Jouberin...
Request Info...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Biology Products:
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... Pacemaker Follow-Up Solution makes convenience and ... our Cardiac Monitoring Center, qualified professionals ... seven days a week for Pacemaker ... time they experience a problem or ...
Medicine Products:
(Date:12/2/2009)... (Nasdaq: PPHM ) today reported completion of patient ... Cotara® in patients with relapsed glioblastoma multiforme (GBM), the ... targeted monoclonal antibody linked to a radioisotope being developed ... specifically targets cells at the center of brain tumors, ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... World, an event bringing together the leaders in ... biotech and MEMS, announced the December 11th deadline ... in its 14th year, TechConnect World, in association ... and the Clean Technology and Sustainable Industries Organization ...
(Date:12/2/2009)... S*BIO Pte Ltd today announced data presentations on its ... of Hematology 51st Annual Meeting and Exposition in New ... results from the Phase 1 dose-escalation trial of SB1518 ... dose levels ranging from 100 to 600 mg. These ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... chemical threats, announced today that the Company is ... of Valortim® in an inhalation anthrax model in ... data are being presented during an oral session ...
(Date:12/4/2009)... HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers ... an acceleration device to enhance orthodontics, announced the ... by PennWell Corporation , a leader in ... dentistry. The course focuses on patient views ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawford presented results ... of secondary end points of biochemical recurrence rate in ... for injection) or monthly leuprolide in prostate cancer patients ... patients who received FIRMAGON 240/80 mg/month had a recurrence ...
Breaking Medicine Technology:PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 1Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 1BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 3Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 1Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 2